CN102225205B - Tripterine nano structure lipid carrier and preparation method and application thereof - Google Patents
Tripterine nano structure lipid carrier and preparation method and application thereof Download PDFInfo
- Publication number
- CN102225205B CN102225205B CN 201110163678 CN201110163678A CN102225205B CN 102225205 B CN102225205 B CN 102225205B CN 201110163678 CN201110163678 CN 201110163678 CN 201110163678 A CN201110163678 A CN 201110163678A CN 102225205 B CN102225205 B CN 102225205B
- Authority
- CN
- China
- Prior art keywords
- tripterine
- lipid carrier
- structured lipid
- preparation
- nano structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid/caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.
Description
Technical field
The present invention relates to field of traditional Chinese, specifically the triterpenes monomer component tripterine of Chinese herb triperygium wilfordii is made preparation method and the application in preparation employing transdermal administration approach treatment psoriasis, rheumatoid arthritis, skin carcinoma and breast cancer medicines of nano structured lipid carrier, described nano structured lipid carrier.
Background technology
Tripterine (Tripterine) is the chemical compound of the pentacyclic triterpene quinone structure that separating-purifying obtains from defend Mao Ke tripterygium plant Radix Tripterygii Wilfordii (Triperygium Wilfordii Hook f.).Molecular formula: C
29H
38O
4, molecular weight: 450.61, CAS number: 34157-83-0, structural formula:
Tripterine is water insoluble, is soluble in dimethyl sulfoxide, chloroform, acetone and ether.Have stronger Immunosuppression reaction, antiinflammatory and antitumaous effect, multiple autoimmune, chronic inflammatory diseases and treatment of cancer be can be used for, psoriasis, atopic dermatitis, skin carcinoma, breast carcinoma, systemic lupus erythematosus and chronic rheumatoid arthritis etc. comprised.Although the reaction of tripterine Immunosuppression, anti-inflammatory and anticancer effect are better, but tripterine is water insoluble, Oral Gastrointestinal Tract absorbs relatively poor, tripterine toxicity is larger in addition, the oral toxic and side effects that can produce general, main manifestations is: there is stimulation in gastrointestinal tract even serious intestinal toxicity occurs; The central nervous system is comprised that Thalamus, midbrain, oblongata, cerebellum and spinal cord produce infringement; Cause the hemorrhage of liver, the heart and necrosis etc.And there is the first pass effect of liver in oral formulations, and bioavailability is low.Adopt the percutaneous dosing mode can improve local drug concentration, the blood drug level peak valley phenomenon of avoiding oral administration etc. to cause reduces the toxic and side effects of the general that produces behind the oral administration; Secondly, can avoid the first pass effect of liver, bioavailability is high; In addition, can reduce administration number of times, prolong dosing interval, easy to use, interruption of the administration reduces drug resistance at any time, and the toxic and side effects of reduction medicine especially toxic medicament, the therapeutic effect of raising medicine are had great clinical value.
Nano structured lipid carrier (nanostructure lipid carriers, NLC) is mixed with the nanoparticle drug administration carrier that obtains at a certain temperature with inconsistent liquid fatty on solid lipid and the space.The lipid skeleton that contains the nanometer compartment by forming some, improve the drug delivery amount, avoid the storage process Chinese medicine to be squeezed, compare with conventional carriers system (such as liposome, microsphere, solid lipid nanoparticle etc.), it has higher Drug loading capacity and reduces the advantage that the storage entrapped drug leaks.Research is found nano structured lipid carrier is used for percutaneous dosing, has good biocompatibility, and skin is had no stimulation; Nano-scale particle can improve cuticular hydration levels, promotes that medicine sees through; Has slow releasing function; Can improve the insoluble drug bioavailability and greatly reduce medicine because of the toxicity of oral generation.
Tripterine is prepared into nano structured lipid carrier, and the mode of employing percutaneous dosing, but the phenomenons such as the scytitis that establishment is caused by psoriasis and hyper-proliferative, the inflammatory reaction of inhibition rheumatoid arthritis, anticancer are bred, and can be reduced the toxic and side effects of tripterine normal tissue.Its treatment advantage aspect psoriasis, rheumatoid arthritis, skin carcinoma and breast carcinoma will have good application and development prospect.Having no at present to have adopts the percutaneous dosing mode to treat the research report of the tripterine nanometer structured lipid carrier of psoriasis, rheumatoid arthritis, skin carcinoma and breast carcinoma effect.
Summary of the invention
Goal of the invention: an object of the present invention is to provide tripterine nanometer structured lipid carrier and preparation method thereof.Another object of the present invention provides the application of nano structured lipid carrier of the present invention in preparation treatment psoriasis, rheumatoid arthritis, skin carcinoma and breast cancer medicines.
For the foregoing invention purpose, the invention provides following technical scheme:
A kind of tripterine nanometer structured lipid carrier is characterized in that containing following component and ratio of weight and number:
Mix lipid 5～100
Wherein mixing lipid is comprised of by 1: 0.1～10: 1 weight ratios solid lipid monoglyceride and liquid fatty caprylic/capric glyceride
Poloxamer-188 0.1～15
Vitamin E polyethylene glycol succinic acid ester (TPGS) 0.5～10.
The preparation method of described a kind of tripterine nanometer structured lipid carrier, it is characterized in that getting a certain amount of mixing matrix material, first with the monoglyceride heat fused, then add caprylic/capric glyceride, phospholipid, TPGS and tripterine, the aqueous phase that contains 1% (w/v) poloxamer-188 that fully fused solution is distributed to uniform temp after the dissolving under the condition of vigorous stirring obtains colostrum, this colostrum is passed through the emulsifying of high pressure dispersing emulsification machine, cooling curing in low temperature water (0-2 ℃) gets final product to get tripterine nanometer structured lipid carrier again.
Described tripterine nanometer structured lipid carrier, its preparation can adopt the form of semisolid or liquid dosage form, such as ointment, gel, emplastrum, spray.Preparation generally includes conventional pharmaceutical carriers or excipient, and can comprise in addition other medicaments, carrier or adjuvant.
The application of described tripterine nanometer structured lipid carrier in preparation employing transdermal administration approach treatment psoriasis.
The application of described tripterine nanometer structured lipid carrier in preparation employing transdermal administration approach treatment medicine for treating rheumatoid arthritis.
The application of described tripterine nanometer structured lipid carrier in preparation employing transdermal administration approach treatment skin carcinoma medicine.
The application of described tripterine nanometer structured lipid carrier in preparation employing transdermal administration approach treatment breast cancer medicines.
The tripterine nanometer structured lipid carrier that the present invention makes, the transmission electron microscope observing drug-carrying nanometer particle is rounded, form regular (seeing accompanying drawing 1 for details), mean diameter is between 95～150nm, potential value has reflected the mutual repulsive force between the particle ,-20mv～-50mv better (seeing accompanying drawing 2,3 for details), redissolve after the lyophilization, particle diameter, current potential are almost unchanged, but long preservation after the lyophilizing.The present invention is because adopting novel adjuvant vitamin E polyethylene glycol succinic acid ester the nanoparticle envelop rate can be increased to 89-98%, and drug loading is increased to 8.2-12%.Check through differential scanning calorimeter (DSC), tripterine has endothermic peak at 175.7 ℃ and 211.4 ℃, after making physical mixture, its endothermic peak of 175.7 ℃ disappears, only deposit 211.4 ℃ endothermic peak, and in tripterine nanometer structured lipid carrier, its endothermic peak complete obiteration (seeing accompanying drawing 4 for details).By A, B, three curve comparisons of C, can find out that the existence form of adjuvant and tripterine all changes in the nano structured lipid carrier, has formed impalpable structure.The formation of this structure can improve the drug loading of lipid, avoids the lipid recrystallization, and keeps α configuration, medicine to be difficult for revealing from nano structured lipid carrier.
Description of drawings
Fig. 1 is tripterine nanometer structured lipid carrier transmission electron microscope photo
Fig. 2 is tripterine nanometer structured lipid carrier potential measurement result
Fig. 3 is tripterine nanometer structured lipid diameter of carrier measurement result
Fig. 4 is the DSC collection of illustrative plates
Beneficial effect
1, nano structured lipid carrier is compared with conventional carriers system (such as liposome, microsphere, solid lipid nanoparticle etc.) and is had higher Drug loading capacity and reduce the advantage that the storage entrapped drug leaks.Tripterine is prepared into nano structured lipid carrier, and adopts the mode of percutaneous dosing, can improve local drug concentration, the blood drug level peak valley phenomenon of avoiding oral administration etc. to cause reduces the general toxicity of the oral rear generation of tripterine; Avoid the first pass effect of liver, bioavailability is high.Secondly, because the good biocompatibility of nano structured lipid carrier is high with cuticular hydration levels, can reduce tripterine to the stimulation of skin, and promote that tripterine sees through.In addition, adopt the percutaneous dosing mode can reduce administration number of times, prolong dosing interval, easy to use, interruption of the administration reduces drug resistance at any time.But the phenomenons such as the scytitis that tripterine nanometer structured lipid carrier establishment is caused by psoriasis and hyper-proliferative, the inflammatory reaction of inhibition rheumatoid arthritis, anticancer propagation, its treatment advantage aspect psoriasis, rheumatoid arthritis, skin carcinoma and breast carcinoma will have great clinical value and good application and development prospect.
2, the present invention adopts novel adjuvant TPGS and phospholipid to prepare tripterine nanometer structured lipid carrier as mixed surfactant, phospholipid has emulsifying capacity and TPGS has emulsifying and oxidation resistance concurrently, both share and within the specific limits can be so that the emulsifying of solid-liquid lipid are complete with proportion control, be unlikely to again emulsifying and excessively in system, form lipid vesicle, prepared nanoparticle particle diameter is even, stability is high, the nanoparticle envelop rate can reach 89-98%, drug loading can be increased to 8.2-12%, significantly improve drug solubility, improve absorption, have stronger skin targeting.The preparation method of the tripterine nanometer structured lipid carrier that the present invention proposes can remedy the defective that has tripterine preparation formulation deficiency now, and preparation method is simple, and production cost is low.
The specific embodiment
Below in conjunction with example the present invention is described in further detail, but scope of the present invention is not subjected to any restriction of these examples.
The preparation of tripterine nanometer structured lipid carrier
Prescription: get tripterine 60mg, monoglyceride 450mg, caprylic/capric glyceride 150mg, phosphatidase 16 0mg, vitamin E polyethylene glycol succinic acid ester 60mg, poloxamer (1%, w/v) 150mL.
Preparation technology: with monoglyceride in 80 ℃ of heat fused, then add caprylic/capric glyceride, phospholipid, vitamin E polyethylene glycol succinic acid ester and tripterine, fully after the dissolving under the condition of vigorous stirring (4000r/min) 150mL that fused solution is distributed to uniform temp is contained poloxamer (1%, w/v) aqueous phase obtains colostrum, this colostrum is passed through high pressure dispersing emulsification machine emulsifying (500bar), circulation 3-6 time; Cooling curing in low temperature water (0-2 ℃) gets final product to get tripterine nanometer structured lipid carrier again.Gained nanoparticle mean diameter is: 102.3nm, and current potential :-38.7mv, envelop rate 97.4%, drug loading are 9.74%.
Embodiment 2
The preparation of tripterine nanometer structured lipid carrier lyophilized powder
Carry out lyophilizing in the tripterine nanometer structured lipid carrier suspension of the mannitol adding embodiment 1 preparation gained with 5%, the obtained freeze-drying powder has good redispersibility, and the particle diameter of nanoparticle, current potential are almost constant behind the redispersion.
Embodiment 3
The preparation of tripterine nanometer structured lipid carrier ointment
With passing through 60 mesh sieves behind the embodiment 2 preparation gained tripterine nanometer structured lipid carrier lyophilized powder porphyrizes, for subsequent use.Taking polyethylene glycol 335040g, PEG400 60g is heated to 65 ℃ in water-bath after mixing, and adds vitamin E 5g and sorbic acid 5g, is stirred to condensation, gets water-soluble ointment base.The tripterine nanometer structured lipid carrier that sieves is added in the above-mentioned substrate, stir and get final product.
Embodiment 4
The preparation of tripterine nanometer structured lipid carrier gel agent
With grinding well in cross linked sodium polyacrylate (SDB-L-400) 5g adding 80mL (60 ℃) water, get gel substrate.Take by weighing PEG-400040g, glycerol 50g, slight fever adds embodiment 2 preparation gained tripterine nanometer structured lipid carrier lyophilized powder mixings to fully dissolving to the beaker, then add in the substrate, mixing, and get final product.
Embodiment 5
The preparation of tripterine nanometer structured lipid carrier emplastrum
Take by weighing sodium polyacrylate 14.2g, polyvinyl alcohol 12.4g, sodium carboxymethyl cellulose 7.1g, gelatin 35.5g, sorbitol 5g add an amount of swelling of water; With kaolin 4.26g, glycerol 78.1g, mix homogeneously after Oleum Ricini 5.32g adds, make semisolid matrix, with adding in the substrate behind embodiment 2 preparation gained tripterine nanometer structured lipid carrier lyophilized powders, an amount of Borneolum Syntheticum and the Mentholum porphyrize, stir, filter, be coated with cream lid lining, section, and get final product.
Embodiment 6
The preparation of tripterine nanometer structured lipid carrier spray
Embodiment 2 preparation gained tripterine nanometer structured lipid carrier lyophilized powders are made fine powder, add an amount of tween 80 mix homogeneously, join again in the aqueous solution that contains sorbic acid and polyvinylpyrrolidone, be uniformly dispersed, be sub-packed in the spray device of regulation and get final product.
Embodiment 7
Preparation according to embodiment 3-6 obtains carries out pharmacodynamic experiment, and wherein drugs compared is tripterine monomer gel, and red pigment monomer gel prepares in accordance with the following methods.
Take by weighing carbopol 940, glycerol and polyoxyethylene sorbitan monoleate and place an amount of distilled water, mixing, and regulate pH to 7.4 with sodium hydroxide solution is dissolved in ethyl hydroxybenzoate adding gradually behind the ethanol again and stirs evenly, and gets clear gel substrate.With the tripterine dissolve with ethanol, add in the substrate, stir evenly namely and get (ethanol final concentration＜1% in the system).
1, the foundation of Cavia porcellus psoriasis model
It is hard of hearing that 5% propranolol ointment evenly is applied to Cavia porcellus, every day 3 times, in continuous 3 weeks, causes Psoriasis-like Model.
2, pharmacodynamic experiment
Get successfully 70 of modeling Cavia porcelluss, be divided at random 7 groups, 10 every group.Every day 1 time, medication 14 days.Administering mode: with medicine coating, spray or be affixed on patient part.The preparation that the 1-4 group obtains for embodiment 3-6, dosage is 2mg tripterine/kg; The 5th group is tripterine monomer gel group, and dosage is 2mg tripterine/kg; The 6th group is the blank matrix group of corresponding preparations; The 7th group is model control group.Next day is put to death Cavia porcellus with the dislocation of cervical vertebra method in drug withdrawal, gets rapidly ear's specimen, places 10% formalin solution to fix.The specimen set time is more than 2 days.With each specimen hierarchy slicing, paraffin embedding is carried out HE dyeing.To the HE stained, under optical microscope 10 (eyepiece) * 20 (object lens) visual field, use the color video camera images acquired, utilize computer image analysis software, choose at random respectively 5 visuals field, carry out the scoring of Baker method tissue and inflammatory cell count to choosing the visual field.Wherein the Baker method is as follows to the standard of psoriatic tissue integration assessment: seeing in the horny layer has the little pus infections of Munro meter 2.0 minutes; Hyperkeratosis meter 0.5 minute; Parakeratosis meter 1.0 minutes.See in the epidermal area granular layer attenuation to be arranged or disappear and counted 1.0 minutes; Acanthosis meter 1.0 minutes; That skin suddenly extends is long, rise and fall, according to light, in, heavy degree counted respectively 0.5,1.0,1.5 minutes.Skin corium is seen has single nuclear and polymorphonuclear cell to infiltrate, according to light, in, heavy degree counted respectively 0.5,1.0,2.0 minutes; The top meter is 0.5 minute on the mastoid process; Telangiectasis meter 0.5 minute.Experimental result sees Table 1.
Table 1 Cavia porcellus Baker scoring and inflammatory cell infiltration assessment of scenario
As can be seen from the above table, blank substrate to psoriasis almost without therapeutical effect, each group of tripterine nanometer structured lipid carrier formulation and red pigment monomer gel all can suppress the development of the psoriasis state of an illness, and each group of tripterine nanometer structured lipid carrier formulation has significant difference (P＜0.05) with red pigment monomer gel in the effect to curing psoriasis.
Embodiment 8
Preparation according to embodiment 3-6 obtains carries out pharmacodynamic experiment, and wherein drugs compared is embodiment 7 preparation gained tripterine monomer gels.
1, the foundation of rat model of rheumatoid arthritis
The preparation of Freund ' s Freund's complete adjuvant: get 1 part after the anhydrous lanolin heating is dissolved and place mortar, slightly cooling adds 2 parts of liquid paraffin while grinding.After grinding 30min, 70 ℃ are total to hot 10min, then add bacillus calmette-guerin vaccine or deactivation tubercule bacillus 7.5mg by every milliliter after the taking-up behind the autoclaving 1h, and grinding is even, and it is for subsequent use to put 4 ℃ of Refrigerator stores, shakes up before the use.Freund ' s Freund's complete adjuvant is injected in Rat Right metapedes Intradermal (0.05mL/ only), and the preparation immune rat is set up the rat model of rheumatoid arthritis.
2, pharmacodynamic experiment
Get successfully 70 of modeling mices, be divided at random 7 groups, 10 every group.Every day 1 time, medication 14 days.Administering mode: with medicine coating, spray or be affixed on patient part.The preparation that the 1-4 group obtains for embodiment 3-6, dosage is 2mg tripterine/kg; The 5th group is tripterine monomer gel group, and dosage is 2mg tripterine/kg; The 6th group is the blank matrix group of corresponding preparations; The 7th group is model control group.Measure rat vola thickness the same day in drug withdrawal, and calculated swelling.Vola thickness before vola thickness-administration after swelling=administration.
Experimental result: the average swelling minimum of each group of tripterine nanometer structured lipid carrier administration group is (2.24 ± 0.23) mm, is up to (2.45 ± 0.37) mm; The average swelling of tripterine monomer gel delivery group is (2.95 ± 0.56) mm; The average swelling of blank matrix group is (3.98 ± 0.63) mm, to almost unrestraint effect of rat paw edema.Each group of tripterine nanometer structured lipid carrier formulation has significant difference (P＜0.05) with the average swelling of red pigment monomer gel.
Embodiment 9
Preparation according to embodiment 3-6 obtains carries out pharmacodynamic experiment, and wherein drugs compared is embodiment 7 preparation gained tripterine monomer gels.
1, the foundation of mouse skin cancer model
The mineral oil that will contain 60%DMBA (DMBA) is coated the skin of back after mice loses hair or feathers, until 10 days.Adopt whether success of GST-π immunohistochemistry staining method detection of skin cancer modeling, use the PAP Cell immunohistochemical staining method, the paraffin section of different lesions specimen is dyeed.The AEC test kit is adopted in the PAP colour developing, and nuclear is redyed with Mayer/s Lignum Sappan rope.GST-π dyes in the normal mouse normal skin and is negative, and develops the color in the squamous cell carcinoma affected skin and is positive.This experimental result shows that institute's modeling type is the skin carcinoma animal model.
2, pharmacodynamic experiment
Get successfully 70 of modeling mices, be divided at random 7 groups, 10 every group.Every day 1 time, medication 14 days.Administering mode: with medicine coating, spray or be affixed on patient part.The preparation that the 1-4 group obtains for embodiment 3-6, dosage is 2mg tripterine/kg; The 5th group is tripterine monomer gel group, and dosage is 2mg tripterine/kg; The 6th group is the blank matrix group of corresponding preparations; The 7th group is model control group.Drug withdrawal next day is put to death mice with the dislocation of cervical vertebra method, uses successively iodine tincture alcohol disinfecting operating position skin, on superclean bench, with the complete tumor skin that strips in sterile working, peels off and claims the tumor weight and by formula calculate tumour inhibiting rate in electronic balance after clean.Tumour inhibiting rate (%)=(the average tumor quality of 1-administration group)/average tumor quality of model control group.
Experimental result: the tumour inhibiting rate minimum of each group of tripterine nanometer structured lipid carrier administration group is 38.1%, is up to 64.3%; Tripterine monomer gel delivery group tumour inhibiting rate is 30.6%; Blank matrix group is to almost unrestraint effect of tumor.Each group of tripterine nanometer structured lipid carrier formulation has significant difference (P＜0.05) with the tumour inhibiting rate of red pigment monomer gel.
Preparation according to embodiment 3-6 obtains carries out pharmacodynamic experiment, and wherein drugs compared is embodiment 7 preparation gained tripterine monomer gels.
1, the foundation of rat breast cancer model
Select female sd inbred rats as laboratory animal.The Walker-256 tumor cell line goes down to posterity by cell culture technology and cultivates amplification, the about 1.5mL of cell suspension (cell number about 1.0 * 10 containing 10% calf serum RPMI-1640
7) plant the Mus intraperitoneal injection, can form ascites tumor after about 1 week.The about 3mL of aseptic extraction ascites, the ascites that takes a morsel dilution and counting, the centrifugal 5min of 800r/min abandons supernatant afterwards, and sedimentation cell is regulated suspension cell concentration to 4.0 * 10 with the dilution of PBS buffer
7/ mL.With rat with 10% chloral hydrate intraperitoneal anesthesia, dorsal position, the sterilization of left side skin of axillary fossa, subcutaneous slow injection cell suspension 0.8mL (cell number about 3.0 * 10
7).Entry needle withdraws from rear point of puncture pin mouth sterilization.
2, pharmacodynamic experiment
Get successfully 70 of modeling mices, be divided at random 7 groups, 10 every group.Every day 1 time, medication 14 days.Administering mode: with medicine coating, spray or be affixed on patient part.The preparation that the 1-4 group obtains for embodiment 3-6, dosage is 2mg tripterine/kg; The 5th group is tripterine monomer gel group, and dosage is 2mg tripterine/kg; The 6th group is respectively the blank matrix group of corresponding preparations; The 7th group is model control group.Drug withdrawal next day is put to death mice with the dislocation of cervical vertebra method, on superclean bench, with the complete tumor that strips in sterile working, peels off and claims the tumor weight and by formula calculate tumour inhibiting rate in electronic balance after clean.Tumour inhibiting rate (%)=(the average tumor quality of 1-administration group)/average tumor quality of model control group.
Experimental result: the tumour inhibiting rate minimum of each group of tripterine nanometer structured lipid carrier administration group is 35.9%, is up to 65.7%; Tripterine monomer gel delivery group tumour inhibiting rate is 32.4%; Blank matrix group is to almost unrestraint effect of tumor.Each group of tripterine nanometer structured lipid carrier formulation has significant difference (P＜0.05) with the tumour inhibiting rate of red pigment monomer gel.
Claims (6)
1. a tripterine nanometer structured lipid carrier is characterized in that, contains following component:
Tripterine 60mg,
Monoglyceride 450mg,
Caprylic/capric glyceride 150mg,
Phosphatidase 16 0mg,
Vitamin E polyethylene glycol succinic acid ester 60mg,
The poloxamer 150mmL of w/v 1%.
2. the preparation method of a kind of tripterine nanometer structured lipid carrier according to claim 1, it is characterized in that, step is: with monoglyceride in 80 ℃ of heat fused, then add caprylic/capric glyceride, phospholipid, vitamin E polyethylene glycol succinic acid ester and tripterine, fully dissolving is rear under the condition of 4000r/min vigorous stirring, the 150mL that fused solution is distributed to uniform temp contains 1%, the aqueous phase of w/v poloxamer obtains colostrum, this colostrum is passed through the emulsifying of 500bar high pressure dispersing emulsification machine, circulation 3-6 time; Cooling curing in 0-2 ℃ of low temperature water gets final product to get tripterine nanometer structured lipid carrier again.
3. the application of a kind of tripterine nanometer structured lipid carrier of claim 1 in preparation employing transdermal administration approach treatment psoriasis.
4. the application of a kind of tripterine nanometer structured lipid carrier of claim 1 in preparation employing transdermal administration approach treatment medicine for treating rheumatoid arthritis.
5. the application of a kind of tripterine nanometer structured lipid carrier of claim 1 in preparation employing transdermal administration approach treatment skin carcinoma medicine.
6. the application of a kind of tripterine nanometer structured lipid carrier of claim 1 in preparation employing transdermal administration approach treatment breast cancer medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110163678 CN102225205B (en) | 2011-06-17 | 2011-06-17 | Tripterine nano structure lipid carrier and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110163678 CN102225205B (en) | 2011-06-17 | 2011-06-17 | Tripterine nano structure lipid carrier and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102225205A CN102225205A (en) | 2011-10-26 |
| CN102225205B true CN102225205B (en) | 2013-03-13 |
Family
ID=44806231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110163678 Expired - Fee Related CN102225205B (en) | 2011-06-17 | 2011-06-17 | Tripterine nano structure lipid carrier and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102225205B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670510B (en) * | 2012-05-02 | 2013-09-18 | 江苏省中医药研究院 | Tripterine nanostructure lipid carrier modified by lentiviral vector and appliance for preparing and treating prostatic cancer, lung cancer and breast cancer drug |
| CN105534881B (en) * | 2015-12-31 | 2019-04-05 | 齐齐哈尔医学院 | A kind of load roxithromycin nano structured lipid carrier gelling agent and preparation method thereof |
| CN106727599A (en) * | 2016-12-13 | 2017-05-31 | 张登海 | A kind of blocking agent of the protein activation of lymphocyte antigen 96 and application thereof |
| CN106880638A (en) * | 2017-02-23 | 2017-06-23 | 中国人民解放军第四军医大学 | Inhibitor, inhibitor combination and the application of the hyper-proliferative of keratinocyte can be suppressed |
| CN107149593A (en) * | 2017-04-11 | 2017-09-12 | 中国人民解放军第三医院八临床部 | Celastrol flexible lipidosome, gel and preparation method thereof |
| CN108159001B (en) * | 2018-01-29 | 2019-08-09 | 安徽工业大学 | A kind of method that the overcritical compression fluid precipitation method prepare tripterine nanometer particle |
| CN108743534B (en) * | 2018-06-20 | 2020-12-15 | 澳门大学 | Tripterine or tripterine derivative vesicle and preparation method thereof |
| CN111437280A (en) * | 2020-04-29 | 2020-07-24 | 重庆燕盈生物科技有限公司 | New application based on tripterine and application thereof |
| CN112665898A (en) * | 2020-12-19 | 2021-04-16 | 河北省微生物研究所 | Method for evaluating quality of leather tissue in leather-making unhairing process of cow leather |
| CN114306280B (en) * | 2022-01-19 | 2023-11-21 | 上海市皮肤病医院 | Application of tripterine nano-drug and IRF1/GSTM3 shaft in preparation of psoriasis drugs |
| CN116196291A (en) * | 2022-12-22 | 2023-06-02 | 沈阳药科大学 | RGD modified tripterine albumin nanoparticle and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1490055A (en) * | 2003-08-28 | 2004-04-21 | 东南大学 | Method for preparing nanometre structure medicine |
| CN101011358A (en) * | 2006-12-29 | 2007-08-08 | 浙江大学 | Nanostructured liposome vector with highly effective antineoplastic activity |
-
2011
- 2011-06-17 CN CN 201110163678 patent/CN102225205B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1490055A (en) * | 2003-08-28 | 2004-04-21 | 东南大学 | Method for preparing nanometre structure medicine |
| CN101011358A (en) * | 2006-12-29 | 2007-08-08 | 浙江大学 | Nanostructured liposome vector with highly effective antineoplastic activity |
Non-Patent Citations (2)
| Title |
|---|
| 李红茹等.《雷公藤复杂提取物脂质体的制备及稳定性研究》.《中国中药杂志》.2007,第32卷(第20期),第2128－2131页. * |
| 陈晶等.《纳米结构脂质载药系统的研究进展》.《药学进展》.2010,第34卷(第12期),第535-541页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102225205A (en) | 2011-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102225205B (en) | Tripterine nano structure lipid carrier and preparation method and application thereof | |
| JP6444308B2 (en) | Tetracycline topical formulation, its preparation and use | |
| CN101947204B (en) | Neo-gambogic acid SLN (solid lipid nanoparticle) and preparation method thereof | |
| CN105663027B (en) | Sirolimus external preparation, preparation method and the usage | |
| CN101366697A (en) | Novel nano-lipid carrier for injection embodying paclitaxel series substances and preparation method thereof | |
| CN105853403A (en) | Paclitaxel palmitate liposome and preparation method thereof | |
| CN104337851A (en) | Preparation method of oleum fructus bruceae nano structure lipid carrier and freeze-dried powder thereof | |
| CN102579323B (en) | Paclitaxel ethosome gel and preparation method thereof | |
| CN103381142A (en) | Ginsenoside Rh1 self-microemulsion composition, and preparation method and application thereof | |
| CN105125592A (en) | Medicine containing toad venom lipid-soluble substances and preparation method thereof | |
| Wang et al. | A lipid micellar system loaded with dexamethasone palmitate alleviates rheumatoid arthritis | |
| Chen et al. | Preparation and evaluation of PEGylated asiatic acid nanostructured lipid carriers on anti-fibrosis effects | |
| CN105456200B (en) | A kind of preparation method and application for the nano mciroball improving insoluble drug oral administration biaavailability | |
| CN1284524C (en) | Application of solid liposome nanoparticle for preparing pharmaceutical used for ion leading-in trandermal therapy | |
| CN104997759B (en) | A kind of total toadpoison lactone solid lipid nano granule drug delivery system of injection and preparation method thereof | |
| CN102846552B (en) | Preparation and application of docetaxel lipid nanoparticle | |
| CN108578356B (en) | Artemether oral microemulsion in-situ gel and preparation method thereof | |
| CN101810577B (en) | Gossypol intravenous injection fatty emulsion for curing tumors | |
| CN108743534B (en) | Tripterine or tripterine derivative vesicle and preparation method thereof | |
| CN101953775A (en) | Hydrogel nanoparticles used as injectable subcutaneous implant agent | |
| CN102670510B (en) | Tripterine nanostructure lipid carrier modified by lentiviral vector and appliance for preparing and treating prostatic cancer, lung cancer and breast cancer drug | |
| CN103690473A (en) | Sinomenine preparation and preparation method thereof | |
| EP2845599B1 (en) | Chinese herbal compound anti-tumour nanopreparation and use thereof | |
| CN102727793A (en) | Yikunning pharmaceutical composition solid lipid nanosphere preparation | |
| CN102670484A (en) | Mannose-modified solid lipid nanoparticle plural gel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 Termination date: 20130617 |